Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01493271 · ClinicalTrials.gov registry record · Phase 2
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
A Phase 2 study of Hypertension, Glaucoma, Open-Angle, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 12
- Study locations
NCT01493271: Completed Phase 2 study of Hypertension, Glaucoma, Open-Angle, sponsored by Hoffmann-La Roche.
NCT01493271 is a Phase 2 study of Hypertension, Glaucoma, Open-Angle that has completed, run by Hoffmann-La Roche. The registered enrollment target is 31 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 12 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01493271, a Phase 2 study of Hypertension, Glaucoma, Open-Angle, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 12
- Study locations
Study Summary
This randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and the effect of RO5093151 on intraocular pressure in patients with ocular hypertension or open angle glaucoma. Patients will be randomized to receive oral doses of RO5093151 or placebo twice daily. The anticipated time on study treatment is 7 days with the possibility to extend to 28 days.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RO5093151
Study Locations (12)
Other
- - Sofia
- - Hradec Králové
- - Litomysi
- - Prague
- - Ústí nad Labem
- - Zlín
- - Budapest
- - Budapest
- - Esztergom
Georgia
- - Morrow
North Carolina
- - High Point
South Carolina
- - Mt. Pleasant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
What the finished NCT01493271 record still lists
NCT01493271 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Hypertension, Glaucoma, Open-Angle appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01493271 lists 12 locations in 4 states (Other, Georgia, North Carolina).
Frequently Asked Questions
What is clinical trial NCT01493271 about?
NCT01493271 is a clinical study titled "A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma". This randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and the effect of RO5093151 on intraocular pressure in patients with ocular hypertension or open angle glaucoma. Patients will be randomized to receive oral doses of RO5093151 or placebo twice daily. The a...
What is the current status of trial NCT01493271?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2011-12. Estimated completion is 2012-11.
What conditions does trial NCT01493271 study?
This clinical trial studies the following conditions: Hypertension, Glaucoma, Open-Angle.
What interventions are being tested in trial NCT01493271?
The interventions under investigation include: Placebo (DRUG), RO5093151 (DRUG).
Who is sponsoring clinical trial NCT01493271?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01493271 being conducted?
This trial has 12 study locations across Georgia, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01493271's enrollment target sits among peer trials
31 1578th of 2000 higher than 419 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia